Nasdaq exas.

11 Okt 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of October.As of October 15th, there was short interest totalling 8,170,000 shares, a ...

9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...Notable Tuesday Option Activity: LTH, DECK, EXAS. January 10, 2023 — 03:23 pm EST. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...

Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.

One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) was up 7.6% during trading on Friday . The company traded as high as $66.06 and last traded at $65.84. Approximately 1,116,388 shares changed hands during trading, a decline of 40% from the average daily volume of 1,860,572 shares. The stock had previously closed at $61.17.Exact Sciences (EXAS) closed the most recent trading day at $65.41, moving +1.93% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.3%. Meanwhile, the Dow gained ...Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...

NASDAQ EXAS opened at $67.03 on Friday. The company has a fifty day moving average of $64.55 and a two-hundred day moving average of $79.14. Exact Sciences Co. has a 1 year low of $43.68 and a 1 ...

Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …Web

Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain. Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders might be concerned after seeing the share price ...On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 92.96 0.00 0.00%. The 17 analysts offering 1 year price forecasts for EXAS have a max estimate of — and a min estimate of —.

According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...Turning to the calls side of the option chain, the call contract at the $39.00 strike price has a current bid of $3.40. If an investor was to purchase shares of EXAS stock at the current price ...Sep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The …WebImportantly, Exact Sciences Corporation (NASDAQ:EXAS) does carry debt. But the more important question is: how much risk is that debt creating? Why Does Debt Bring Risk? Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take ...

Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.

This year, Exact Sciences (EXAS-1.63%) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%. The company ...Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate Nov 15. No longer forecast to breakeven Nov 03. Third …WebDec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ... MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... 1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03.Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...

Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The …Web

Exact Sciences EXAS continues to make significant progress with its Cologuard test. The integration of PreventionGenetics also buoys optimism. Escalating expenses, its sole reliance on Cologuard ...

Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WebEXAS is in a good position to continue its growth. Acquisitions seem to have unlocked new value. ... (NASDAQ: EXAS) as a "buy" at a 1-year price target of $150 (+13% upside) with a strong further ...Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents: Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate Nov 15. No longer forecast to breakeven Nov 03. Third …WebStock Market Today: Stocks lower, Nvidia and Tesla slide, Gold retreats from record high. Investors are betting on at least five Fed interest-rate cuts next ...MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment ...Published. May 23, 2022 11:22AM EDT. Exact Sciences Corporation EXAS is well-poised for growth, backed by impressive first-quarter 2022 results. Further, the company’s legacy Screening business ...Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...

16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00. EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...Instagram:https://instagram. nernxtd ameritrade vs schwabpsk stockpeach state healthcare After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...Exact Sciences Corporation’s EXAS legacy Screening business is witnessing significant improvement, buoyed by Cologuard volume growth. However, escalating costs and stiff competition are concerning. fjiabuy chainlink The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts. target price for stocks Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Exact Sciences Corporation Common Stock (EXAS) Nasdaq Listed; ... Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ...